CN Patent

CN121226255A — 一种达罗他胺衍生物及其制备方法与用途

Assigned to Anhui Yipuke Pharmaceutical Technology Development Co ltd · Expires 2025-12-30 · 0y expired

What this patent protects

本发明涉及一种式I化合物或其盐或其溶剂化物，式Ⅰ化合物的制备方法或其药物组合物及其用途。式I化合物可用于制备治疗高危转移风险的非转移性去势抵抗性前列腺癌成年患者药物，具有长效低毒的优点。

USPTO Abstract

本发明涉及一种式I化合物或其盐或其溶剂化物，式Ⅰ化合物的制备方法或其药物组合物及其用途。式I化合物可用于制备治疗高危转移风险的非转移性去势抵抗性前列腺癌成年患者药物，具有长效低毒的优点。

Drugs covered by this patent

Patent Metadata

Patent number
CN121226255A
Jurisdiction
CN
Classification
—
Expires
2025-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Anhui Yipuke Pharmaceutical Technology Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.